Home / Stocks / Zydus Lifesciences Ltd
ZYDUSLIFE

Zydus Lifesciences Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,202.9

Change

+0.9 (0.07%)

Open

₹1,195.0

Prev. Close

₹1,202.0

Day High

₹1,203.0

Day Low

₹1,185.2

Volume Analysis

Traded

713,800

Delivered

496,858

Delivery %

69.61%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (21.2%)
  • •Strong operating margin (27.0%)

Weaknesses (0)

No signal for this stock

Opportunities (3)

  • •Strong 3-year EPS growth (37.3%)
  • •Strong 3-year revenue growth (16.4%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,226.66 ₹1,214.83 ₹1,208.86 ₹1,197.03 ₹1,191.06 ₹1,179.23 ₹1,173.26
Fibonacci ₹1,214.83 ₹1,208.03 ₹1,203.83 ₹1,197.03 ₹1,190.23 ₹1,186.03 ₹1,179.23
Camarilla ₹1,207.8 ₹1,206.16 ₹1,204.53 ₹1,197.03 ₹1,201.27 ₹1,199.64 ₹1,198.01

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+31.46%

1 Week

-0.26%

1 Month

+7.66%

3 Months

+7.4%

6 Months

+15.78%

1 Year

+29.62%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹560.75

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

13.88%

Net margin 14.16% × asset turnover 0.49x × equity multiplier 2.0x

Company Overview

Sector

Healthcare

Market Cap

₹118,693 Cr

P/E (TTM)

26.2

ROE

21.2%

Book Value

₹279.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Zydus Lifesciences Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 71/100. The strongest factor is Liquidity (99/100), while Cash Flow (14/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (21.2%); strong operating margin (27.0%). Strong 3-year EPS growth (37.3%).

TopFund Score — Fundamentals Quality

71/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

88

Growth

86

Valuation

47

Cash Flow

14

Corporate Governance

60

Momentum

82

Institutional Ownership

44

Business Quality

88

Risk & Volatility

85

Liquidity

99

From Screener.in

  • +Company has delivered good profit growth of 18.8% CAGR over last 5 years

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

USFDA inspection at LiqMeds, UK ended with 4 observations on November 13, 2026.

Zydus completed subscription and 50:50 joint venture in Zydus Sunshine on November 11, 2026.

Transcript of the post results earnings call held on November 4, 2026.

Zydus Therapeutics reports Phase 2b saroglitazar data: 39.1% and 32.4% response vs 13.7% placebo.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 4,369 4,505 5,534 6,208 5,237 5,269 6,528 6,574 6,123 6,864 7,587 8,017 7,910
Expenses + 3,223 3,403 3,903 4,124 3,776 3,882 4,402 4,485 4,107 5,048 5,033 6,088 6,015
Operating Profit 1,146 1,102 1,630 2,084 1,461 1,388 2,126 2,088 2,016 1,816 2,554 1,929 1,894
OPM % 26.0% 24.0% 29.0% 34.0% 28.0% 26.0% 33.0% 32.0% 33.0% 26.0% 34.0% 24.0% 24.0%
Other Income + 53 60 160 63 68 57 -139 155 75 26 -263 126 159
Interest 9 20 35 32 25 32 77 85 101 130 123 156 187
Depreciation 184 195 205 215 234 229 238 238 302 360 508 530 604
Profit before tax 1,006 947 1,550 1,900 1,271 1,184 1,672 1,921 1,687 1,353 1,660 1,369 1,262
Tax % 22.0% 23.0% 21.0% 23.0% 29.0% 15.0% 25.0% 23.0% 27.0% 29.0% 19.0% 26.0% 26.0%
Net Profit + 803 790 1,246 1,482 920 1,026 1,244 1,521 1,239 1,023 1,341 1,011 928
EPS in Rs 8 8 12 14 9 10 12 15 13 10 13 10 9
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 6 6 10 21 20 17 18 6 17 30 16 22 29

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 8,651 9,427 9,376 11,905 13,166 14,253 14,404 15,110 17,237 19,547 23,242 27,148 30,378
Expenses + 6,896 7,095 7,474 9,074 10,174 11,455 11,013 11,768 13,378 14,163 16,183 18,673 22,183
Operating Profit 1,756 2,332 1,902 2,831 2,991 2,798 3,391 3,342 3,860 5,384 7,058 8,475 8,195
OPM % 20.0% 25.0% 20.0% 24.0% 23.0% 20.0% 24.0% 22.0% 22.0% 28.0% 30.0% 31.0% 27.0%
Other Income + 45 112 127 111 183 -264 -231 2,581 -422 293 50 -7 48
Interest 68 53 45 91 194 342 159 127 130 81 166 439 596
Depreciation 287 292 373 539 599 696 670 713 723 764 916 1,408 2,002
Profit before tax 1,446 2,099 1,612 2,312 2,382 1,495 2,331 5,084 2,585 4,832 6,027 6,621 5,644
Tax % 18.0% 8.0% 8.0% 24.0% 22.0% 21.0% 8.0% 10.0% 23.0% 20.0% 23.0% 24.0% —
Net Profit + 1,188 1,964 1,517 1,810 1,899 1,204 2,185 4,618 2,092 3,973 4,673 5,124 4,302
EPS in Rs 11 19 15 17 18 11 21 44 19 38 45 50 42
Dividend Payout % 21.0% 17.0% 22.0% 20.0% 19.0% 30.0% 17.0% 6.0% 31.0% 8.0% 24.0% 2.0% —
Sales growth 20 9 -1 27 11 8 1 5 14 13 19 17 24

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 4,149 5,597 6,858 8,642 10,284 10,273 12,890 16,897 17,415 19,729 23,852 27,011 27,718
Borrowings + 2,651 2,442 5,207 5,407 7,899 7,986 4,608 4,221 1,195 804 3,213 12,496 13,966
Other Liabilities + 2,144 2,208 2,937 3,632 4,945 5,115 6,165 6,421 6,851 8,201 9,523 11,065 13,823
Total Liabilities 9,047 10,350 15,104 17,783 23,231 23,477 23,765 27,642 25,562 28,834 36,689 50,673 55,607
Fixed Assets + 3,352 3,748 5,755 6,483 12,164 12,230 12,133 12,188 11,521 12,368 13,134 24,106 27,698
CWIP 798 951 1,543 1,527 837 742 783 726 1,201 2,423 2,692 3,698 1,636
Investments 154 416 435 746 674 765 830 3,288 1,547 1,220 6,412 7,540 8,348
Other Assets + 4,743 5,235 7,371 9,028 9,556 9,740 10,019 11,439 11,294 12,822 14,451 15,328 17,925
Total Assets 9,047 10,350 15,104 17,783 23,231 23,477 23,765 27,642 25,562 28,834 36,689 50,673 55,607
Equity Capital 102 102 102 102 102 102 102 102 101 101 101 101 100

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 994 1,894 1,312 919 1,282 2,932 3,294 2,104 2,689 3,196 6,781 2,117
Cash from Investing Activity + -465 -860 -2,872 -974 -3,977 -1,004 -837 -1,018 1,542 -1,492 -8,363 -7,895
Cash from Financing Activity + -351 -935 2,316 52 1,885 -1,528 -2,548 -868 -4,400 -1,779 1,995 5,807
Net Cash Flow 178 99 756 -3 -811 399 -90 219 -170 -75 414 28
Free Cash Flow 498 936 -1,623 -116 236 2,043 2,447 1,050 1,697 2,313 5,139 -530
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 79 109 81 54 65 116 107 83 85 83 122 44

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 74.98% → 75.01%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 6.99% 6.66% 6.81% 6.85% 6.85% 6.69% 6.74% 6.81% 6.86% 6.86% 6.83% 6.66%
Promoters 74.98% 74.98% 74.98% 74.98% 74.98% 75.0% 75.0% 75.0% 75.0% 75.0% 75.02% 75.01%
Government 0.07% 0.07% 0.07% 0.05% 0.05% 0.05% 0.04% 0.0% 0.0% 0.0% 0.0% 0.0%
FII 4.99% 5.72% 5.59% 7.52% 7.53% 7.31% 7.13% 7.34% 7.06% 6.95% 6.89% 7.05%
DII 12.96% 12.55% 12.56% 10.59% 10.61% 10.95% 11.09% 10.86% 11.08% 11.2% 11.27% 11.28%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Zydus Lifesciences Ltd (this stock) 118,693 26.2 4.27 21.2%
Dr. Reddy S Laboratories 115,092 41.1 2.96 11.2%
Cipla Ltd 112,563 36.2 3.18 11.6%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Mankind Pharma Limited 108,424 46.5 6.16 13.1%
Aurobindo Pharma Ltd 104,215 25.7 2.64 10.1%

Which Mutual Funds Hold Zydus Lifesciences Ltd?

Frequently Asked Questions about Zydus Lifesciences Ltd

Community Sentiment

What are other investors saying about Zydus Lifesciences Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.